Location of Repository

An Antibiotic-Responsive Mouse Model of Fulminant Ulcerative Colitis

By Silvia S Kang, Seth M Bloom, Lyse A Norian, Michael J Geske, Richard A Flavell, Thaddeus S Stappenbeck and Paul M Allen

Abstract

Paul Allen and colleagues describe the development of a mouse model of fulminant ulcerative colitis with multiple genetic hits in immune regulation which can be moderated by anti-cytokine therapy and broad-spectrum antibiotics

Topics: Research Article
Publisher: Public Library of Science
OAI identifier: oai:pubmedcentral.nih.gov:2270287
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    Preview

    Citations

    1. (1997). A CD4þ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis.
    2. (2006). A genome-wide association study identifies IL23R as an inflammatory bowel disease gene.
    3. (2001). A major quantitative trait locus on chromosome 3 controls colitis severity in IL-10-deficient mice.
    4. (2003). A murine model of Madurella mycetomatis eumycetoma.
    5. (1997). A role for TNF-alpha and mucosal T helper-1 cytokines in the pathogenesis of Crohn’s disease.
    6. (2000). Abrogation of TGFbeta signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease.
    7. (2005). Activated macrophages are an adaptive element of the colonic epithelial progenitor niche necessary for regenerative responses to injury.
    8. (2003). Antibiotics with a selective aerobic or anaerobic spectrum have different therapeutic activities in various regions of the colon in interleukin 10 gene deficient mice.
    9. (1995). Antibodies to interleukin 12 abrogate established experimental colitis in mice.
    10. (2004). Antiinterleukin-12 antibody for active Crohn’s disease.
    11. (2006). Antimicrobials in the management of inflammatory bowel disease.
    12. (2001). CD25þ CD4þ T cells regulate the expansion of peripheral CD4 T cells through the production of IL-10.
    13. (2006). Cellular mechanisms of fatal earlyonset autoimmunity in mice with the T cell-specific targeting of transforming growth factor-beta receptor.
    14. (2006). Characterization of Foxp3þCD4þCD25þ and IL-10-secreting CD4þCD25þ T cells during cure of colitis.
    15. (2003). Colitogenic Th1 cells are present in the antigen-experienced T cell pool in normal mice: control by CD4þ regulatory T cells and IL-10.
    16. (2003). critical cytokine for autoimmune inflammation of the brain.
    17. (2004). de Waal Malefyt R
    18. (2007). Development of the human infant intestinal microbiota.
    19. (2001). Different subsets of enteric bacteria induce and perpetuate experimental colitis in rats and mice.
    20. (2006). Differential activity of IL-12 and IL-23 in mucosal and systemic innate immune pathology.
    21. (2005). Differentiation of Tr1 cells by immature dendritic cells requires IL-10 but not CD25þCD4þ Tr cells.
    22. (1996). Disparate CD4þ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn’s disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5.
    23. (1996). Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(þ) TH1-like responses.
    24. (2005). Experimental models of inflammatory bowel disease reveal innate, adaptive, and regulatory mechanisms of host dialogue with the microbiota.
    25. (1997). Fedorak RN
    26. (1996). Gastrointestinal tract. Ackerman’s Surgical Pathology.
    27. (1989). Generation and characterization of hamster monoclonal antibodies that neutralize murine tumor necrosis factors.
    28. (1998). Helicobacter hepaticus triggers colitis in specific-pathogen-free interleukin-10 (IL-10)-deficient mice through an IL-12- and gamma interferondependent mechanism.
    29. (2000). Heritable susceptibility for colitis in mice induced by IL-10 deficiency.
    30. (2003). IL-10 and TGF-beta induce alloreactive CD4þCD25- T cells to acquire regulatory cell function.
    31. (2006). IL-22 is increased in active Crohn’s disease and promotes proinflammatory gene expression and intestinal epithelial cell migration.
    32. (2006). IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6.
    33. (2006). IL-23 plays a key role in Helicobacter hepaticus-induced T cell-dependent colitis.
    34. (2002). In vitro generation of interleukin 10-producing regulatory CD4(þ) T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)- and Th2-inducing cytokines.
    35. (1996). Inflammatory bowel disease in C.B-17 scid mice reconstituted with the CD45RBhigh subset of CD4þ T cells.
    36. (2007). Inflammatory bowel disease: clinical aspects and established and evolving therapies.
    37. (1994). Inhibition of Th1 responses prevents inflammatory bowel disease in scid mice reconstituted with CD45RBhi CD4þ T cells.
    38. (1993). Interleukin-10-deficient mice develop chronic enterocolitis.
    39. (2005). Interleukin-22, a member of the IL-10 subfamily, induces inflammatory responses in colonic subepithelial myofibroblasts.
    40. (2006). Interleukin-23 drives innate and T cell-mediated intestinal inflammation.
    41. (2004). Interleukin10 and related cytokines and receptors.
    42. (2005). Keratin-8-deficient mice develop chronic spontaneous Th2 colitis amenable to antibiotic treatment.
    43. (1998). Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF.
    44. (1985). Monoclonal antibodies to murine gamma-interferon which differentially modulate macrophage activation and antiviral activity.
    45. (1992). Mutations in T-cell antigen receptor genes alpha and beta block thymocyte development at different stages.
    46. (1997). Neutralization of tumour necrosis factor (TNF) but not of IL-1 reduces inflammation in chronic dextran sulphate sodium-induced colitis in mice.
    47. (2000). Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12.
    48. (1991). O’Garra A
    49. (2005). Optimizing therapy in patients with pancolitis.
    50. (2004). Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis.
    51. (2001). Regulatory activity of autocrine IL-10 on dendritic cell functions.
    52. (1998). Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice.
    53. (1995). T cells in inflammatory bowel disease: protective and pathogenic roles.
    54. (2005). T cells that cannot respond to TGF-beta escape control by CD4(þ)CD25(þ) regulatory T cells.
    55. Targan SR (2000) Role of cytokines in the pathogenesis of inflammatory bowel disease.
    56. (2003). Targeting enteric bacteria in treatment of inflammatory bowel diseases: why, how, and when.
    57. (2002). The immunology of mucosal models of inflammation.
    58. (2002). The interrelated roles of TGF-beta and IL-10 in the regulation of experimental colitis.
    59. (1998). The orphan receptor CRF2–4 is an essential subunit of the interleukin 10 receptor.
    60. (2007). The straw that stirs the drink: insight into the pathogenesis of inflammatory bowel disease revealed through the study of microflora-induced inflammation in genetically modified mice.
    61. (2006). Transforming growth factor-beta controls development, homeostasis, and tolerance of T cells by regulatory T cell-dependent and -independent mechanisms.
    62. (2006). Transforming growth factor-beta regulation of immune responses.
    63. (1995). Ulcerative colitis and adenocarcinoma of the colon in G alpha i2-deficient mice.
    64. (2007). Ulcerative colitis.
    65. (2007). Unravelling the pathogenesis of inflammatory bowel disease.
    66. (2006). Use of antibiotics in the treatment of inflammatory bowel disease.

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.